These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21288101)

  • 41. CYP2C19 genotype and proton pump inhibitors in clopidogrel-treated patients: does it take two to tango?
    O'Donoghue ML
    Circulation; 2011 Feb; 123(5):468-70. PubMed ID: 21262991
    [No Abstract]   [Full Text] [Related]  

  • 42. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
    Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T
    Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
    Tang XF; Zhang JH; Wang J; Han YL; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
    Chin Med J (Engl); 2013 Mar; 126(6):1069-75. PubMed ID: 23506580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical-scientific notes.
    Dick RJ; Byron KA; Dear AE
    Intern Med J; 2012 Oct; 42 Suppl 5():7-8. PubMed ID: 23035675
    [No Abstract]   [Full Text] [Related]  

  • 45. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome.
    Park KJ; Chung HS; Kim SR; Kim HJ; Han JY; Lee SY
    Korean J Lab Med; 2011 Apr; 31(2):91-4. PubMed ID: 21474982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost is not a barrier to implementing clopidogrel pharmacogenetics.
    Cavallari LH; Schumock GT
    Pharmacotherapy; 2012 Apr; 32(4):299-303. PubMed ID: 22461119
    [No Abstract]   [Full Text] [Related]  

  • 49. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
    Price MJ; Tantry US; Gurbel PA
    Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
    Ono T; Kaikita K; Hokimoto S; Iwashita S; Yamamoto K; Miyazaki Y; Horio E; Sato K; Tsujita K; Abe T; Deguchi M; Tayama S; Sumida H; Sugiyama S; Yamabe H; Nakamura S; Nakagawa K; Ogawa H
    Thromb Res; 2011 Dec; 128(6):e130-6. PubMed ID: 21862109
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations.
    Angiolillo DJ; Ueno M
    JACC Cardiovasc Interv; 2011 Apr; 4(4):411-4. PubMed ID: 21511220
    [No Abstract]   [Full Text] [Related]  

  • 52. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiplatelet therapy: Does CYP2C19 genotype affect clinical outcome?
    ten Berg JM; Deneer VH
    Nat Rev Cardiol; 2012 Mar; 9(4):192-4. PubMed ID: 22411289
    [No Abstract]   [Full Text] [Related]  

  • 54. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?
    Bhatt DL
    JAMA; 2009 Aug; 302(8):896-7. PubMed ID: 19706866
    [No Abstract]   [Full Text] [Related]  

  • 56. Impact of clopidogrel response on the clinical evolution in patients with acute coronary syndromes.
    Costache II; Rusu C; Ivanov I; Popescu R; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):962-7. PubMed ID: 23700873
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).
    Wynn RL
    Gen Dent; 2010; 58(1):7-9. PubMed ID: 20129886
    [No Abstract]   [Full Text] [Related]  

  • 58. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study.
    Fontana P; James R; Barazer I; Berdagué P; Schved JF; Rebsamen M; Vuilleumier N; Reny JL
    J Thromb Haemost; 2011 Aug; 9(8):1664-6. PubMed ID: 21692977
    [No Abstract]   [Full Text] [Related]  

  • 59. Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting.
    Sibbing D; Bernlochner I; Kastrati A; Paré G; Eikelboom JW
    Circ Cardiovasc Interv; 2011 Oct; 4(5):505-13; discussion 513. PubMed ID: 22010189
    [No Abstract]   [Full Text] [Related]  

  • 60. What's new about clopidogrel.
    Cialdella P; Gustapane M; Camaioni C; Biasucci LM
    Minerva Cardioangiol; 2013 Dec; 61(6):683-9. PubMed ID: 24253460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.